Primary care in the treatment of functional gastrointestinal symptoms in Japan: Prescription preferences and impression of results

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 21, Issue 2, 2005, Pages 47-54

  Hongo, M ^a   Kanatsuka, H ^a   Sugawara, A ^a   Nagasaki, Y ^a   Endo, Y ^a   Karahashi, K ^a   Shoji, T ^a   Sagami, Y ^a   Aoki, I ^a  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; GASTROINTESTINAL AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; KAMPO; POLYCARBOPHIL; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

ANOREXIA; ARTICLE; CLUSTER ANALYSIS; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; HEARTBURN; HUMAN; JAPAN; NAUSEA; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUESTIONNAIRE;

EID: 20444422211     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02474.x     Document Type: Article

References (23)

1. Talley NJ. Dyspepsia. Management guidelines for the millennium. Gut 2002; 50 (Suppl. 4): iv72-8.
2. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, et al. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001; 96: 689-96.
3. Cardin F, Zorzi M, Furlanetto A, et al. Are dyspepsia management guidelines coherent with primary care practice? Scand J Gastroenterol 2002; 37: 1269-75.
4. Mones J, Guilera M, Artes M, et al. Criteria used by general practitioners in prescribing prokinetic or antisecretory drugs in patients with functional dyspepsia. Rev Esp Enferm Dig 2001; 93: 281-92.
5. Enck P, Dubois D, Marquis P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999; 231: 48-54.
6. Fraser A, Delaney B, Moayyedi P. Symptom-based outcome measures for dyspepsia and GERD trials: a systematic review. Am J Gastroenterol 2005; 100: 442-52.
7. Haycox A, Einarson T, Eggleston A. The health economic impact of upper gastrointestinal symptoms in the general population: Results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999; 231: 38-47.
8. Glise H, Hallerback B, Wiklund I. Quality of life: a reflection of symptoms and concerns. Scand J Gastroenterol Suppl 1996; 221: 14-7.
9. Whitehead WE, Corazziari E, Prizont ER, et al. Definition of a responder in clinical trials for functional gastrointestinal disorders: report on a symposium. Gut 1999; 45 (Suppl. II): II78-9.
10. Veldhuyzen van Zanten SJO, Talley NJ, Bytzer P, et al. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45 (Suppl. II): II69-77.
11. Veldhuyzen van Zanten SJ, Cleary C, Talley NJ, et al. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 1996; 91: 660-73.
12. Spiller RC. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med 1999; 107: 91S-7.
13. van Pinxteren B, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2001; CD002095.
14. DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology. Arch Intern Med 1995; 155: 2165-73.
15. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
16. Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2004; CD001960.
17. Talley NJ, Lauritsen K. The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies. Gut 2002: 50 (Suppl. 4): iv36-41.
18. 2- receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials. Aliment Pharmacol Ther 2001; 15: 1291-9.
19. Lewin van den Broek NT, Numans ME. Buskens E, et al. A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome. Br J Gen Pract 2001; 51: 619-24.
20. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004; 127: 1239-55.
21. Talley NJ, Weaver AL, Tesmer DL, et al. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology 1993; 105: 1378-86.
22. Matsueda K. Guidelines for dyspepsia treatment in Japan. Clin Ther 1998: 20 (Suppl. D): D13-21.
23. Hongo M, Sagami Y. Pharmacological treatment of dyspeptic symptoms. Progr Med 1999; 19: 2024-7 (in Japanese).